Risk Factors of Thromboembolism in Lymphoma Patients Undergoing Chemotherapy and its Clinical Significance
This study investigated the risk factors of thromboembolism (TE) in lymphoma patients undergoing chemotherapy and its clinical significance. A total of 304 lymphoma patients who received chemotherapy from January 2012 to July 2019 were retrospectively analyzed, including 111 patients with and 193 pa...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-09-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296211037923 |
| _version_ | 1819081760702464000 |
|---|---|
| author | Xiao Li MM Shu-Ling Hou MM Xi Li MM Li Li MM Ke Lian MM Ju-Ya Cui MM Gang-Gang Wang MM Tao Yang PhD |
| author_facet | Xiao Li MM Shu-Ling Hou MM Xi Li MM Li Li MM Ke Lian MM Ju-Ya Cui MM Gang-Gang Wang MM Tao Yang PhD |
| author_sort | Xiao Li MM |
| collection | DOAJ |
| description | This study investigated the risk factors of thromboembolism (TE) in lymphoma patients undergoing chemotherapy and its clinical significance. A total of 304 lymphoma patients who received chemotherapy from January 2012 to July 2019 were retrospectively analyzed, including 111 patients with and 193 patients without TE. The clinical characteristics and related laboratory test results were compared between the 2 groups using univariate analysis, while the risk factors for TE in lymphoma patients undergoing chemotherapy were analyzed using multivariate logistic regression analysis. Univariate analysis revealed an increase in the risk of TE among lymphoma patients with chemotherapy in the following categories: female patients, patients with body mass index <18.5 or > 24, patients aged ≥60 years, those with platelet abnormality before chemotherapy, single hospital-stay patients, and Ann Arbor stage III/IV patients. Multivariate logistic regression analysis revealed that for platelet count abnormality before chemotherapy, Ann Arbor stage III/IV and female patients represented independent risk factors for TE among lymphoma patients after chemotherapy ( P < .05). For lymphoma patients treated with chemotherapy, the risk of TE occurring in women, patients with platelet abnormalities before chemotherapy, and patients at Ann Arbor stage III/IV was significantly higher compared with other patients. For these patients, we recommend prophylactic anticoagulant therapy. |
| first_indexed | 2024-12-21T20:05:54Z |
| format | Article |
| id | doaj.art-a7daabd62d3a4c6bb795ad8d20107bf5 |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-12-21T20:05:54Z |
| publishDate | 2021-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-a7daabd62d3a4c6bb795ad8d20107bf52022-12-21T18:51:51ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232021-09-012710.1177/10760296211037923Risk Factors of Thromboembolism in Lymphoma Patients Undergoing Chemotherapy and its Clinical SignificanceXiao Li MM0Shu-Ling Hou MM1Xi Li MM2Li Li MM3Ke Lian MM4Ju-Ya Cui MM5Gang-Gang Wang MM6Tao Yang PhD7 Department of Thoracic Oncology, Linfen Central Hospital, Linfen, China Bethune Hospital Affiliated to Shanxi Medical University, , Taiyuan, China Bethune Hospital Affiliated to Shanxi Medical University, , Taiyuan, China Bethune Hospital Affiliated to Shanxi Medical University, , Taiyuan, China Bethune Hospital Affiliated to Shanxi Medical University, , Taiyuan, China Bethune Hospital Affiliated to Shanxi Medical University, , Taiyuan, China Bethune Hospital Affiliated to Shanxi Medical University, , Taiyuan, China Bethune Hospital Affiliated to Shanxi Medical University, , Taiyuan, ChinaThis study investigated the risk factors of thromboembolism (TE) in lymphoma patients undergoing chemotherapy and its clinical significance. A total of 304 lymphoma patients who received chemotherapy from January 2012 to July 2019 were retrospectively analyzed, including 111 patients with and 193 patients without TE. The clinical characteristics and related laboratory test results were compared between the 2 groups using univariate analysis, while the risk factors for TE in lymphoma patients undergoing chemotherapy were analyzed using multivariate logistic regression analysis. Univariate analysis revealed an increase in the risk of TE among lymphoma patients with chemotherapy in the following categories: female patients, patients with body mass index <18.5 or > 24, patients aged ≥60 years, those with platelet abnormality before chemotherapy, single hospital-stay patients, and Ann Arbor stage III/IV patients. Multivariate logistic regression analysis revealed that for platelet count abnormality before chemotherapy, Ann Arbor stage III/IV and female patients represented independent risk factors for TE among lymphoma patients after chemotherapy ( P < .05). For lymphoma patients treated with chemotherapy, the risk of TE occurring in women, patients with platelet abnormalities before chemotherapy, and patients at Ann Arbor stage III/IV was significantly higher compared with other patients. For these patients, we recommend prophylactic anticoagulant therapy.https://doi.org/10.1177/10760296211037923 |
| spellingShingle | Xiao Li MM Shu-Ling Hou MM Xi Li MM Li Li MM Ke Lian MM Ju-Ya Cui MM Gang-Gang Wang MM Tao Yang PhD Risk Factors of Thromboembolism in Lymphoma Patients Undergoing Chemotherapy and its Clinical Significance Clinical and Applied Thrombosis/Hemostasis |
| title | Risk Factors of Thromboembolism in Lymphoma Patients Undergoing Chemotherapy and its Clinical Significance |
| title_full | Risk Factors of Thromboembolism in Lymphoma Patients Undergoing Chemotherapy and its Clinical Significance |
| title_fullStr | Risk Factors of Thromboembolism in Lymphoma Patients Undergoing Chemotherapy and its Clinical Significance |
| title_full_unstemmed | Risk Factors of Thromboembolism in Lymphoma Patients Undergoing Chemotherapy and its Clinical Significance |
| title_short | Risk Factors of Thromboembolism in Lymphoma Patients Undergoing Chemotherapy and its Clinical Significance |
| title_sort | risk factors of thromboembolism in lymphoma patients undergoing chemotherapy and its clinical significance |
| url | https://doi.org/10.1177/10760296211037923 |
| work_keys_str_mv | AT xiaolimm riskfactorsofthromboembolisminlymphomapatientsundergoingchemotherapyanditsclinicalsignificance AT shulinghoumm riskfactorsofthromboembolisminlymphomapatientsundergoingchemotherapyanditsclinicalsignificance AT xilimm riskfactorsofthromboembolisminlymphomapatientsundergoingchemotherapyanditsclinicalsignificance AT lilimm riskfactorsofthromboembolisminlymphomapatientsundergoingchemotherapyanditsclinicalsignificance AT kelianmm riskfactorsofthromboembolisminlymphomapatientsundergoingchemotherapyanditsclinicalsignificance AT juyacuimm riskfactorsofthromboembolisminlymphomapatientsundergoingchemotherapyanditsclinicalsignificance AT ganggangwangmm riskfactorsofthromboembolisminlymphomapatientsundergoingchemotherapyanditsclinicalsignificance AT taoyangphd riskfactorsofthromboembolisminlymphomapatientsundergoingchemotherapyanditsclinicalsignificance |